Table 2 Associations between inflammatory proteins and mortality among patients with gallbladder cancer in Shanghai.

Inflammatory proteins	No. of patients	No. of deaths	Adjusted HRs	Adjusted median survival (months)^b
Inflammatory proteins	No. of patients	(% of patients)	(95% CIs)^a	Adjusted median survival (months)^b
CCL19
Q1	34	22 (64.7)	1.00	11.1
Q2	33	29 (87.9)	1.49 (0.82, 2.72)	7.7
Q3	34	32 (94.1)	2.08 (1.13, 3.82)	3.9
Q4	33	31 (93.9)	2.86 (1.58, 5.17)	3.1
P trend^c			2.2 × 10⁻⁴
CCL20
Q1	34	25 (73.5)	1.00	8.2
Q2	33	28 (84.8)	1.82 (1.05, 3.17)	5.2
Q3	34	30 (88.2)	2.62 (1.50, 4.58)	3.9
Q4	33	31 (93.9)	2.49 (1.41, 4.41)	3.1
P trend^c			6.3 × 10⁻⁴
CRP
Q1	34	22 (64.7)	1.00	10.0
Q2	33	29 (87.9)	1.84 (1.02, 3.34)	5.2
Q3	34	33 (97.1)	2.51 (1.36, 4.62)	3.7
Q4	32	29 (90.6)	2.90 (1.58, 5.32)	2.9
P trend^c			3.3 × 10⁻⁴
IL-6
Q1	34	22 (64.7)	1.00	8.2
Q2	33	31 (93.9)	1.78 (0.98, 3.21)	5.2
Q3	34	29 (85.3)	1.72 (0.94, 3.12)	3.9
Q4	32	31 (96.9)	3.02 (1.66, 5.48)	3.1
P trend^c			7.0 × 10⁻⁴
sTNFRI
Q1	34	26 (76.5)	1.00	10.0
Q2	33	24 (72.7)	1.35 (0.76, 2.39)	5.1
Q3	34	34 (100.0)	3.82 (2.22, 6.57)	3.5
Q4	31	29 (93.5)	2.56 (1.43, 4.59)	2.6
P trend ^c			2.9 × 10⁻⁵
sTNFRII
Q1	34	23 (67.6)	1.00	12.3
Q2	33	29 (87.9)	1.36 (0.75, 2.49)	7.6
Q3	34	31 (91.2)	2.40 (1.31, 4.38)	3.5
Q4	31	30 (96.8)	3.77 (1.98, 7.19)	2.2
P trend^c			7.9 × 10⁻⁶
sVEGFR3
Q1	34	26 (76.5)	1.00	8.1
Q2	33	27 (81.8)	2.59 (1.44, 4.66)	5.0
Q3	34	33 (97.1)	2.81 (1.61, 4.90)	3.7
Q4	31	27 (87.1)	2.56 (1.40, 4.67)	3.2
P trend^c			1.3 × 10⁻⁴
TRAIL
Q1	34	32 (94.1)	1.00	2.9
Q2	33	28 (84.8)	0.46 (0.27, 0.80)	3.7
Q3	34	30 (88.2)	0.63 (0.37, 1.08)	5.2
Q4	33	24 (72.7)	0.26 (0.14, 0.47)	10.0
P trend^c			8.3 × 10⁻⁵

^aAdjusted for age groups (≤54, 55–65, or ≥66 years), sex, clinical stage (early or late), and ever had cholecystectomy (yes/no), stratified by lot. ^bAdjusted for clinical stage (early or late). ^cTwo-sided P values for trend across marker categories were assessed with the Wald test using categorical values of the proteins with 1 degree of freedom.

Search